SILO licensing their patent nasal spray

Updated
SILO has one of the first patent-pending nasal spray making psilocybin easier to access, administer and ingest. They've signed last week a licensing agreement with Brasil and Colombia and expecting now that market penetration in LATAM to continue. This marks the Company’s first commercial transaction of its new-to-world intellectual property and I believe that with this market currently developping, they will reach several other licensing deals which means immediate revenue starting to come in for them (at the opposite of many R&D companies in psilocybin market trying to create revenue in the long term). Price has been fairly stable between .20-.25 over the past month despite market pull-back, which calls for a solid support floor and entry level. I'm invested with an average of .22 and decided to buy more with this morning's small pull-back. This is no financial advise, do your DD, but I see this stock start moving up as they begin announcing their first licensing revenus in the coming quarters.
Note
They also have recently signed a multi-year license agreement with the family of legendary musician Bob Marley and are opening Psychedelic Wellness Retreat/clinics, including a few in 2021 already. Check their website for details, but I see them becoming one of the few companies in this space generating revenus quickly from here.
Note
Again, this is not a buy recommendation nor a finacial advise, do your DD.
Note
NEWS: Silo Pharma Submits Application for NASDAQ up-listing (Globenewswire)

These guys a seriously moving, yet the stock remains at a great accumulation level for when the NASDAQ approval will be granted.
Beyond Technical Analysislicensingrevenue

Disclaimer